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doi:10.1016/j.ejvs.2009.09.010Abstract Objective: To assess whether limitations of randomised controlled trials (RCTs) of
endovascular aneurysm repair (EVAR) can be addressed by evidence from non-randomised
studies.
Design: Analysis of data from a systematic review.
Methods: We conducted a review of EVAR versus open repair or non-surgical management of
abdominal aortic aneurysms. In addition to RCTs, we included pre-specified registries of EVAR
and open repair.
Results: The six included RCTs randomised patients in 2003 and earlier. Of the three registries
included, one contributed data on a large (>8000) sample of patients treated with newer
generation EVAR devices and followed up for up to 8 years. However, treatment dates of these
patients overlapped with those of the RCTs. The other registries were of limited usefulness. A
large (>45,000) controlled observational study published while the review was in progress
broadly supported the findings of RCTs comparing EVAR with open surgery. A comparison of
outcomes across all studies did not support the hypothesis that the findings of the RCTs are
no longer representative of clinical practice.
Conclusions: Both randomised and non-randomised sources of evidence have strengths and
weaknesses for assessing the effectiveness of EVAR. Further research should explore the
optimum use of registry data, including patient-level analyses.
Crown Copyright ª 2009 Published by Elsevier Ltd on behalf of European Society for Vascular
Surgery. All rights reserved.1904 321097; fax: þ44 0 1904 321041.
(D. Chambers).
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This paper considers the role of non-randomised evidence
alongside RCT evidence in a systematic review of endo-
vascular aneurysm repair (EVAR) for abdominal aortic
aneurysms (AAA). The objective of the review was to
evaluate the effectiveness of EVAR compared with open
surgical repair and non-surgical management. Based on
a previous systematic review of surgical procedures1 we
recognised that data from RCTs for a procedure like EVAR
might be limited. Furthermore, the relevant RCTs of EVAR
were initiated between 1996 and 2000. There is evidence of
a gradual improvement in outcomes of EVAR from 1992 to
20022 and such improvements over time would reduce the
applicability of RCT findings to current practice. We
therefore expanded the inclusion criteria for studies look-
ing at the effectiveness of EVAR to include publications
derived from registry data. The continuing evolution of
EVAR devices and increased experience with the procedure
meant that analyses of registry data could potentially
provide more current estimates of outcomes after EVAR as
well as having larger samples and longer periods of follow-
up. This paper evaluates the contribution of RCT and
registry evidence to the review and discusses relevant
methodological aspects and developments to optimise the
use of non-randomised data in future systematic reviews.
Methods
The systematic review was performed to inform the
development of guidance by the National Institute for
Health and Clinical Excellence (NICE) and was therefore
required to reflect best current practice of direct relevance
to the UK NHS. We included RCTs and published reports
from pre-specified registries that evaluated EVAR in
patients with asymptomatic or symptomatic, ruptured or
unruptured infrarenal AAAs. The comparators of interest
were conventional open repair for patients for whom this
was a treatment option and non-surgical management for
patients for whom open repair was not considered a treat-
ment option. Studies were required to report on 30-day
operative mortality, aneurysm-related or all-cause
mortality at follow-up, health-related quality of life
(HRQOL), adverse events and complications or re-inter-
vention rates.
To determine which registries should be included in the
review we took advice from clinical experts and considered
all potentially relevant registries, i.e. those that were
mainly or partly UK based and included data on EVAR or
open repair of AAA. The registries that met these criteria
were RETA and EUROSTAR for EVAR and the National
Vascular Database for open repair of AAA. These were
therefore named as the pre-specified registries to be
included in this review. These registries were treated as
large case series and were used to derive estimates of
outcomes following EVAR and open repair in routine clinical
practice.
Recent systematic reviews by Drury et al3 and Lederle
et al4 were used to identify randomised controlled trials
(RCTs) and other clinical studies. We examined the
systematic review by Drury et al. 3 and decided a priori thatit would not be useful to search for further controlled
observational studies or case series. Additional searches
were conducted to identify recent RCTs (2005e7) and
publications relating to named registries. We sought the
most recent report of outcome data for each registry.
The following bibliographic databases were searched:
BIOSIS Previews (R); CINAHL; The Cochrane Central Register
of Controlled Trials; EMBASE; ISI Proceedings, MEDLINE(R);
MEDLINE(R) In-Process & Other Non-Indexed Citations;
Science Citation Index; Zetoc Conferences. Searches were
not restricted by language or study design. Regular current
awareness searches were carried out during the review
using both Science Direct and Zetoc and covered the period
up to February 2008. The Medicare population study dis-
cussed below5 was identified from a current awareness
search.
Two reviewers independently screened all titles and
abstracts. Potentially relevant full paper manuscripts were
obtained where possible, and the relevance of each study
was assessed independently by two reviewers. At each
stage of the review process disagreements or discrepancies
were resolved by discussion with reference to a third
reviewer if necessary.
Data relating to study design, quality and outcomes of
interest were extracted by one reviewer and checked by
a second. For registries, data were extracted from the
latest report covering the outcomes of interest.
The quality of the individual RCTs was assessed by one
reviewer and independently checked for agreement by
a second reviewer. The quality of RCTs was assessed using
standard checklists6 that were adapted to incorporate
topic-specific quality issues. The quality of audit/registry
data was not assessed because the included registries were
chosen for relevance and pre-specified in the protocol.
Data extracted from the studies were tabulated and
discussed in a narrative review. When appropriate, meta-
analysis was carried out using fixed-effect models using
Review Manager 4.2 (the Cochrane Collaboration). A
spreadsheet developed by the MRC Clinical Trials Unit,
London, was used to estimate hazard ratios where
necessary.7
Results
Search results
The flow of studies through the review is shown in Fig. 1. Six
RCTs and reports from three registries were included. In
addition, a large study of the outcomes of EVAR and open
repair in US Medicare recipients was published while the
review was in progress.5 Although it did not meet the
inclusion criteria for the systematic review, it provided
evidence relevant to the review question because of its
very large sample size and matched group study design.
Study characteristics are summarised in Table 1.
Study characteristics and limitations
RCTs
Four of the included RCTs (DREAM8,9, EVAR trial 110e12 and
the studies by Cuypers et al.13 and Soulez et al.14)
Titles and abstracts  
identified and screened  
n=4691 
Excluded n=4012 
Not relevant n=3862* 
Records of research in progress n=150 
Excluded n=587
Patient group not AAA n=19 
RCT but not EVAR vs Open or non-surgical n=8 
Registry other than RETA, EUROSTAR or NVD n=3 
Not RCT or Registry (e.g. non-randomised trials, case series, 
review articles etc.) n=552 
Duplicate n=5 
Total number of studies included n=9 
RCTs n=6 (19 publications) 
Registries n=3 (75 publications)** 
Full copies retrieved and screened for inclusion 
n=679
Figure 1 Flow chart of studies through the review process. *Excluded based on title and abstract. **Registry publications rep-
resenting the latest report on outcomes of interest from the whole registry (five publications) were selected for data extraction
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tured AAAs who were fit for both procedures. One RCT
(EVAR trial 215) compared EVAR with non-surgical manage-
ment of patients deemed unfit for open repair. A small RCT
by Hinchliffe et al.16 compared EVAR and open repair in
patients with ruptured AAA.
The main RCTs of unruptured AAA repair, DREAM,9 EVAR
trial 111 and EVAR trial 2,15 were all of high-quality (positive
answers to all quality questions). Some methodological
aspects of the remaining RCTs were unclear based on the
published reports (data not shown). Sample sizes of all RCTs
were relatively small (Table 1), the largest being EVAR trial 1
(1082 patients).
The small studies by Cuypers et al.13 and Soulez et al.14
were not designed to assess hard clinical endpoints such as
mortality as primary outcomes; furthermore, the study of
Cuypers et al. was limited to one month of follow-up.
Hence the analysis of EVAR versus open repair for unrup-
tured AAAs concentrated on data from the two larger RCTs.
The major trials comparing EVAR with open repair,
DREAM8,9 and EVAR trial 110,11, randomised patients
between November 2000 and December 2003 and between
September 1999 and December 2003, respectively. Thus the
devices used and other details of the procedures do not
represent current best practice. Published results from
the two RCTs represent relatively short periods of follow-up
(2 years for DREAM and 4 years for EVAR trial 1). The main
analyses of EVAR trial 1 were published in 2004 for 30-day
operative mortality10 and 2005 for 4-year follow-up
results11 and covered patients randomised up to December
2003. Finally, the sample size calculation for DREAM was
based on a primary endpoint of short-term mortality and
complications and the trial’s power to detect differences in
follow-up outcomes is unclear.The only RCT to have compared EVAR with continued
non-surgical management of patients considered unfit or
unsuitable for open repair is EVAR trial 2.15 Although this
was a high-quality RCT in terms of design and methodology,
there were problems with its execution. There was
a median delay of 57 days between randomisation and
procedure in the EVAR arm and 14 patients in this group
died before their operation (including six from AAA
rupture). Forty-seven patients assigned to non-surgical
management received surgical aneurysm repair (including
12 who received open repair despite having been classified
as unfit for this procedure). These factors complicate the
analysis and interpretation of this trial.
The evidence base for EVAR for patients with ruptured
AAAs is currently limited to one very small pilot trial.16 The
sample size calculation for this trial was based on recruiting
100 patients, but only 32 patients were randomised, which
makes it difficult to draw any firm conclusions from the trial.
Registries
The EUROSTAR report17 presented data on patient and
operative characteristics and short- and long-term follow-
up outcomes. For each follow-up point, data were pre-
sented on endoleaks and other complications. Life tables
and KaplaneMeier curves were presented for survival,
freedom from endoleak, freedom from secondary inter-
vention and freedom from rupture. In addition to this large
and long-term case series of EVAR, EUROSTAR has been
used for a variety of studies of different designs (case-
control and cohort) on factors influencing prognosis after
EVAR. The RETA registry data were used for subgroup
analyses of operative outcome by type of device, aneurysm
size and patient fitness.18 Data on open repair from the NVD
have been analysed in terms of outcome by age, serum
Table 1 Study characteristics.
Comparison Sample size Dates registered/treated Length of follow-up Mortality outcomes
30d AR AC
RCTs
DREAM8,9 EVAR vs. open 351 November 2000eDecember 2003 Mean 22 months
Maximum 42 months
O O O
EVAR 110e12 EVAR vs. open 1082 September 1999eDecember 2003 Median 2.9 years
Maximum >4 years
O O O
Cuypers et al. 13 EVAR vs. open 76 September 1996eOctober 1999 30 days O  
Soulez et al. 14 EVAR vs. open 40 September 1998-July 2002 9e48 months O  *
EVAR 215 EVAR vs. non-surgical management 338 September 1999eDecember 2003 Median 2.4 years O O O
Hinchliffe et al. 16 EVAR vs. open (ruptured AAA) 32 September 2002eDecember 2004 30 days O  
Registries
EUROSTAR17,20 EVAR only 8345 Up to June 2006 Minimum 30 days
Maximum 96 months
O  O
RETA18,22,26 EVAR only 1000 January 1996eMarch 2000 Minimum 30 days O O O
Maximum 5 years
NVD19 Open only 4545 1999eMarch 2004 In-hospital only** O  
Matched cohort study
Medicare study. 5 EVAR vs. open 45,660 2001e2004 Up to 5 years O O O
*Only one death during follow-up **Not explicitly stated but expected to be 30 days or less. Mortality outcomes: 30d, 30-day; AR, aneurysm-related; AC, all-cause.
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30 D. Chambers et al.creatinine and other factors, and used to develop and test
risk scoring models.19
Comparison of EUROSTAR and RETA demonstrated the
greater clinical relevance of EUROSTAR for the assessment
of EVAR. In addition to the greater number of cases and
centres included (1000 cases from 41 UK centres for RETA,
and 8345 from 177 centres for EUROSTAR), EUROSTAR
specified entry requirements for centres and patients were
registered prospectively by participating centres20; RETA did
not have specific requirements and cases were submitted on
a voluntary basis, raising the risk of selection bias. Patients
were registered and treated up to June 2006 for EUROSTAR,
and between January 1996 and March 2000 for RETA. Given
the rapid evolution of EVAR devices and technique and
growing experience the data from the RETA registry are
therefore very out of date. While the EUROSTAR data also
included some procedures using now obsolete devices, the
latest report from EUROSTAR17 explicitly excluded any data
relating to ‘older’ devices and included only those patients
treated with the newer generation of endografts.
The NVD report 19 included 4545 cases of open repair
from 59 centres in the UK. As with RETA, cases were
submitted voluntarily and there were no specific require-
ments for centres to be included. The report covered
patients treated between 1999 and March 2004. Timeliness
is less of an issue in evaluating open repair than for EVAR
because the technique is well established and not subject
to rapid change. Limitations of the NVD data for the
purposes of this review were the short period of follow-up
and limited outcomes reported. Furthermore, since the
NVD only includes a minority of the open repair procedures
performed in England,21 the reliability of mortality esti-
mates derived from the registry is uncertain.
Medicare population study
This study5 used administrative data to identify Medicare
beneficiaries who had undergone elective AAA repair during
2001e2004. To control for non-random assignment of
patients to procedures, the authors created matched
cohorts of patients after constructing logistic regression
models that predicted the likelihood of undergoing EVAR
(propensity score). Each patient who underwent EVAR was
matched with the patient with the closest propensity score
who underwent open repair.
Important features of this study were that it used a large
sample drawn from routine clinical practice, although
reflecting practice in the USA rather than the UK. Patients
were followed to the 4-year time point, comparable to
published data from the EVAR trial 1 RCT. The finding of an
early mortality benefit from EVAR but no difference
between groups in the longer-term is similar to the data
from EVAR trial 1 and DREAM trials. The study provides
important data on the relationship between age and the
benefit of EVAR relative to open repair. It also identified
a higher rate of laparotomy-related complications in the
open repair group: such complications were not taken into
account in previous analyses.5 This suggests that the
increased risk of non-AAA-related re-interventions
following open repair may offset the increased risk of AAA-
related re-interventions following EVAR.
Limitations of the study reflect its non-randomised
design and its reliance on administrative data. The use ofpropensity scoring could not rule out differences between
groups in unknown or unmeasured factors. Data on aneu-
rysm size were not available in the administrative data-
base, so it is difficult to say whether the populations
included patients not meeting UK guidelines for AAA repair.
Similarly, anatomical suitability for EVAR could not be
determined, so it is unclear how many patients were
assigned to open repair because they were not suitable for
EVAR.5Outcome data
Mortality data from the three study types are summarised
in Table 2.
RCTs
Compared with open repair EVAR reduced operative
mortality (OR 0.35 (95% CI: 0.19, 0.63)) and aneurysm-
related mortality over the medium term (estimated hazard
ratio 0.49 (95% CI: 0.29, 0.83)) but offered no significant
difference in all-cause mortality at mid-term follow-up.
EVAR was associated with an increased rate of complica-
tions and re-interventions and these were not offset by any
increase in HRQOL. EVAR trial 2 found no significant
differences in mortality outcomes between EVAR and non-
surgical management at any follow-up point.
Registries
EUROSTAR presented outcomes for short-term (30-day) and
long-term (96 months/8 years) mortality, with 190 (2.3%)
deaths occurring within 30 days and 789 (9.5%) during the
follow-up period (Table 2). KaplaneMeier survival analysis
reported the cumulative number of deaths as 979 and
mortality rate of 39%.
In RETA, 58 patients (5.8%) died within 30 days18 and
9 patients were reported to have died from fatal rupture
(aneurysm-related mortality) at follow-up (6 (0.8%) at
1 year and 3 (0.8%) at 2 years). 22 A cumulative rate of all-
cause mortality was not reported, although figures were
presented for each year of follow-up: 11.9% mortality in
year 1 and 10%, 8% and 7.9% at 2, 3, and 4 years post-
procedure.
The NVD reported mortality rates following open repair
for the 30-day period only, with an overall crude mortality
rate of 14.8% (95% CI: 13.7e16.0%).19 Crude mortality rates
for ruptured and unruptured AAAs were 41% (95% CI: 37.7,
44.3%) and 6.8% (95% CI: 5.9, 7.8%) respectively.
Medicare population study
Mortality within 30 days was 1.2% after EVAR and 4.8% after
open repair (relative risk 0.25, 95% CI 0.22, 0.29,
p< 0.001), an absolute difference of 3.6%. The relative risk
estimate was similar to those seen in the DREAM and EVAR 1
RCTs, but with a narrower confidence interval because of
the larger sample size.
The absolute advantage of EVAR over open repair
increased with increasing age: from 2.1% absolute risk
reduction at 67e69 years to 8.5% at 85 years or older. The
early survival benefit from EVAR persisted for about 3 years
in the whole population, after which time the survival
curves were similar. The benefit lasted less than 18 months
Table 2 Mortality data for EVAR and open repair from RCTs, registries and Medicare population study.
Source Follow-up 30-day mortality Aneurysm-related
mortality at follow-up
All-cause mortality
at follow-up
EVAR
DREAM (EVAR arm)8, 9 Mean 22 months
Maximum 42 months
1.2% 2.1% 10.3%
EVAR trial 1
(EVAR arm)10-12
Minimum: 12 months
Maximum: 5 years
Median: 2.9 years
1.7% 4% (4-year point
estimate)
26% (4-year
point estimate)
EUROSTAR17 Minimum: 30 days
Maximum: 96 months
(8 years)
2.3% Not reported 23% (4 years)
39% (8 years)
RETA 22 Minimum: 30 days
Maximum: 5 years
Mean: 3.1 years
5.8% Fatal rupture
at 1 year 0.8%
Fatal rupture at
2 years 3 0.8%
At 1 year 11.9%
1e2 years 10%
2e3 years
8% 3e4 years 7.9%
Medicare study
(EVAR group)5
Maximum: 5 years 1.2% Rupture 1.8% Not reported
(survival curves presented)
Open repair
DREAM
(open repair arm)8, 9
Mean 22 months
Maximum 42 months
4.6% 5.7% 10.4%
EVAR trial 1
(open repair arm)10e12
Minimum: 12 months
Maximum: 5 years
Median: 2.9 years
4.7% 7% (4-year point
estimate)
29% (4-year
point estimate)
NVD19 Not reported 6.8%
(95% CI: 5.9e7.8%)*
Not reported Not reported
Medicare study
(open repair group)5
Maximum: 5 years 4.8% Rupture 0.5% Not reported (survival
curves presented)
*Crude mortality for repair of unruptured aneurysm.
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those aged 85 years and older.
Strengths and limitations of different
evidence types
The strengths and limitations of the different types of
evidence included in the review are summarised in Table 3
and discussed further below.
Discussion
EVAR is relatively unusual for a surgical intervention in
having evidence from good quality RCTs, especially EVAR
1 and 2 and DREAM, to evaluate its effectiveness relative to
open repair and non-surgical management. However, these
trials randomised patients between 1999 and 2003 and we
therefore questioned whether the devices used and results
obtained in the EVAR arm reflect what can be achieved in
current practice. A systematic review by Franks et al.
reported that operative mortality, rupture and endoleak all
fell significantly between 1992 and 2002.2 Recent devel-
opments in EVAR devices include the introduction of
extra-stiff guidewires, better delivery systems and stent
grafts with a larger range of sizes, while polymer-filled
devices are under development.23 These advances have
increased the number of patients potentially suitable for
EVAR by reducing the anatomical limitations. In thesecircumstances, it seems reasonable to assume some
improvement in practice between 2002 and the present,
and therefore to consider evidence from more recent, if
non-randomised, sources in evaluating EVAR.
A crude comparison of mortality outcomes across the
different study types (Table 2) indicates that the non-
randomised sources broadly supported the findings of the
main RCTs comparing EVAR and open repair. 30-day
mortality rates were similar between the EVAR arms of
EVAR trial 1 and DREAM and the EUROSTAR registry, as was
cumulative all-cause mortality at equivalent follow-up
points. The Medicare population study5 showed a similar
pattern to the RCTs, with the early survival advantage of
EVAR over open repair disappearing over time. Thus,
consideration of relevant non-randomised evidence did not
support the hypothesis that the findings of the RCTs are no
longer representative of clinical practice.
The different types of evidence discussed in this paper
all have strengths and weaknesses (Table 3). Registries by
definition have no control group but they may provide
useful ‘real world’ information on outcomes post-inter-
vention. Of the registries specified for inclusion in the
EVAR review, EUROSTAR was by far the most useful.
EUROSTAR provided larger samples and longer follow-up
than did the RCTs for evaluation of mortality and compli-
cations. Long-term follow-up after EVAR is important to
assess outcomes related to device durability (e.g. re-
interventions and device migration) as well as longer-term
survival.
Table 3 Strengths and limitations of different evidence types.
Strengths Weaknesses
RCTs Example: EVAR 1 Randomised study design
Allocation concealment
Balanced treatment groups
Sample size calculation
Analysis by intention-to-treat
Blinded outcome assessment
Entry criteria for centres (minimises
‘learning curve’ effect)
Representative of UK practice
Intervention not representative of
current practice
Entry criteria for centres (possible
over-representation of more expert centres)
Relatively short follow-up
Registries Example: EUROSTAR Large sample size
Entry criteria for centres (minimises
‘learning curve’ effect)
Prospective registration
Latest report covers ‘newer generation’
of EVAR devices
Relatively long follow-up
No control group
Possible selection bias in reports
Entry criteria for centres (possible
over-representation of more expert centres)
Matched cohort study Example:
Medicare study
Large sample size
Balanced treatment groups
Representative population
Non-random treatment allocation
Use of administrative data (limited outcomes,
non-blinded assessment)
Possibly not representative of UK practice
32 D. Chambers et al.This report from EUROSTAR was restricted to more
recent devices and hence the outcomes may be more
reflective of current practice than those in RCTs. Other
than the lack of a control group, the other main limitation
of the EUROSTAR registry was the uncertainty about how
representative the self-selected centres and surgeons
included in the registry are of outcomes achieved with
EVAR across Europe. In comparing outcomes of EVAR
between EUROSTAR and the EVAR arm of EVAR 1, it should
be borne in mind that the EUROSTAR population includes
a substantial proportion (24.7%) of patients considered unfit
for open repair.17 Furthermore, the aneurysm diameter of
the EUROSTAR population ranged from 30 to 172 mm,17
meaning that some of the patients treated with EVAR had
aneurysms too small to be considered for open repair under
current guidelines.
The large matched cohort Medicare study by Scher-
merhorn et al.5 generally supported the findings of the
RCTs but also provided additional information. Because of
its large sample size this study included a larger number of
elderly patients than the studies included in the systematic
review and the findings indicated that the survival benefit
of EVAR may be greater in the older than the younger
age groups. This finding is in line with evidence, for
example from the Swedish Vascular Registry,24 of an
increasing trend to use EVAR in older patients.
The included registries were pre-specified and chosen
for relevance to UK practice, but this means that other
registries with potentially relevant data were excluded.
Formal quality assessment of registries was not under-
taken. A framework for quality assessment of registries
has been developed25 but is very extensive and would
require co-operation with registry owners for completion,
making its use in most systematic reviews not practi-
cable. We relied on published reports from registries andwere therefore limited by the availability of published
results.
The inclusion of the Medicare population study by
Schermerhorn et al. 5 could be seen as either a strength or
a limitation of the review. The inclusion criteria for the
review specified that only RCTs and named registries would
be included in the effectiveness review and hence the
Schermerhorn study did not formally meet the criteria.
However, after consideration of its relevance and quality it
was included in the evidence base for the review as
a source of comparative evidence of the outcomes of EVAR
and open repair in clinical practice. Had the study been
published before rather than during the review, it is likely
that the inclusion criteria would have been written differ-
ently. We believe that overall, the contribution of this
study strengthened the review and it should be taken into
account in designing future systematic reviews in this area.
Unsurprisingly, our analysis of the RCTs reached similar
conclusions to the study of Lederle et al.4. There have
been no newly published RCTs although a number of
trials are ongoing. The French ACE (Elective Abdominal
Aortic Aneurysm e Open Versus Endovascular Repair;
ClinicalTrials.gov identifier NCT00224718) trial started in
January 2003 and was completed in February 2009, with
a planned 4-year follow-up (http://clinicaltrials.gov/show/
NCT00224718, accessed 29 April 2009). The RCT evidence
for EVAR relative to open repair should be reviewed again
when the results of this trial are available.
Previous systematic reviews of EVAR have either been
restricted to RCTs4 or have included non-randomised
evidence in the form of non-randomised trials, comparative
observational studies and case series. 2,3 We decided to
exclude most non-randomised studies from our review after
examining the review by Drury et al.3; most of the included
comparative studies were small and did not follow the type
Non-randomised Evidence in Systematic Review of EVAR 33of matching procedure used by Schermerhorn et al., 5 so it
was unclear whether groups were comparable. Our
approach was to include non-randomised evidence where
this might address perceived limitations of the RCTs. The
EUROSTAR registry data did not produce any startling
insights although it did suggest that the outcomes of EVAR
reported in the EVAR 1 and DREAM titles have not been
invalidated by recent advances. There is a need for further
exploration of the ways in which registry data might be
used in systematic reviews. We treated registries as case
series and used results from published reports to evaluate
outcomes, but registry data may be suitable for a range of
other analyses. If collaborations between registry owners
could be established, individual patient data analyses could
be considered.
As a general conclusion, in addition to RCTs future
systematic reviews could potentially benefit from including
country-specific registries because of their relevance to
local practice and large registries or population studies to
assess the generalisability of the RCT results.
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